ARCA biopharma receives method patent for treatment with bucindolol predicated on genetic targeting ARCA biopharma, Inc ed doctor . , a biopharmaceutical business developing genetically targeted therapies for cardiovascular diseases, announced that the U today.S. Patent and Trademark Office has issued a patent on options for determining whether to administer or prescribe bucindolol to a patient based on whether the patient has a specific genotype – homozygous for the arginine 389 polymorphism in the beta-1 adrenergic receptor. The patent entitled ‘Options for Treatment with Bucindolol Based on Genetic Targeting,’ provides intellectual residence protection in the United States for this novel approach to treating individuals with bucindolol.
The record also reveals Crimson Cross’s apparent nationwide practice of violating workers rights under federal labor laws and regulations. We believe there is a strong connection between keeping high requirements for donor and bloodstream safety, and employing well-qualified and experienced frontline blood drive workers, who perform their critical duties under suitable working conditions. For the past 15 years, the ARC provides been under a federal government court order to improve just how it collects and processes blood. Since 2003 the Federal Drug Administration offers fined the business $21 million with regards to lapses in bloodstream safety. Lately, the FDA billed the Red Cross with a fresh round of bloodstream managing violations in two adverse perseverance letters sent to the Red Cross on October 30, 2009.